Evidence map›Paper›PMID 42656851›Full record

ArticleFrontiers in microbiology2026

Lead optimization of 3-indoleacetonitrile identifies candidate compounds with improved anti-influenza activity and safety profiles.

Xianfeng Hui, Shihuan Ding, Bingqi Yan, Junlong Wang, Jingyun Zhang, Shuochen Xu, Rujing Zhang, Shuoxiang Gao, Tiesuo Zhao, Xiaowei Tian and 1 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xianfeng Hui *Department of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Shihuan Ding *Department of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Bingqi YanDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Junlong WangLuoyang Central Hospital Affiliated to Henan Medical University, Luoyang, China.
Jingyun ZhangDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Shuochen XuDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Rujing ZhangDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Shuoxiang GaoDepartment of Pathogenic Biology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Tiesuo ZhaoDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Xiaowei TianDepartment of Pathogenic Biology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.
Hui WangDepartment of Immunology, School of Basic Medical Sciences, Henan Medical University, Xinxiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Influenza A virus (IAV) remains a major respiratory pathogen that causes substantial morbidity, mortality, and socioeconomic burden worldwide. Although several antiviral agents are available for clinical use, their effectiveness is often compromised by the emergence of drug-resistant variants, limited therapeutic windows, and potential adverse effects. Small-molecule antivirals represent an important strategy for influenza treatment; however, improving antiviral efficacy while minimizing toxicity remains a major challenge in drug development. In this study, we sought to identify candidate low-toxicity derivatives structurally related to 3-indoleacetonitrile, a previously characterized compound with anti-influenza activity. Methods: Candidate compounds were selected through a computational screening strategy integrating structural similarity analysis, toxicity prediction, and drug-likeness assessment. Cytotoxicity was evaluated by CCK-8 assays and morphological observation in A549 cells. Antiviral activity was assessed using a recombinant luciferase-expressing PR8 influenza virus. Promising candidates were subsequently evaluated in a lethal influenza mouse model challenged with 10 × LD50 PR8 virus. Body weight changes, survival rates, lung pathology, viral burden, and serum AST/ALT levels were analyzed to determine antiviral efficacy and safety Results: Four candidates-Indole-3-ethanol, Indole-3-acetamide, 3-Indoleacetic acid, and Acetohydroxamic acid-were identified. Cytotoxicity analyses revealed that Indole-3-ethanol and Indole-3-acetamide exhibited substantially lower toxicity than the parent compound 3-indoleacetonitrile, maintaining high cell viability at concentrations exceeding 640 μM. Morphological examination further confirmed their improved safety profiles. In antiviral assays, Indole-3-ethanol and Indole-3-acetamide demonstrated potent inhibition of IAV replication, while 3-Indoleacetic acid and Acetohydroxamic acid showed little or no detectable antiviral activity. Conclusion: Structural optimization of the lead compound 3-indoleacetonitrile led to the identification of derivatives with improved antiviral activity and reduced toxicity. Among the compounds evaluated, Indole-3-ethanol exhibited the most favorable balance between efficacy and safety, demonstrating potent anti-influenza activity in both cell-based and animal models. These findings support the utility of computationally guided lead optimization and identify Indole-3-ethanol as a promising candidate for further development as an anti-influenza therapeutic.

Indexed as

3-indoleacetonitrileantiviral therapyindole-3-ethanolindole derivativesinfluenza A virussmall-molecule antivirals

Identifiers

PMID42656851
PMCPMC13506958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.